The earnings call highlighted significant progress with FDA approvals and strong trial retention. Financial stability and expansion opportunities in additional indications were also emphasized. However, there were delays in timeline for topline data and a reduction in trial size, indicating some operational adjustments.

Company Guidance -

Q2 2025

During the Ocular Therapeutix Fourth Quarter 2024 Earnings Conference Call, significant updates were shared regarding the registrational program for AXPAXLI in wet AMD. The FDA approved an amendment to the SOL-1 study's special protocol agreement, allowing redosing at weeks 52 and 76, aiming to secure a six to 12-month dosing label. This amendment is expected to enhance the drug's potential as a long-lasting treatment option. As a result, topline data for SOL-1 is now anticipated in the first quarter of 2026. The SOL-R study was optimized, reducing its size from 825 to 555 subjects while maintaining a robust statistical power of 90%. This change aims to accelerate the timeline for reporting data and regulatory submission. The company reported strong financial health with a cash balance of $392 million, projecting sufficient funding into 2028 without plans to raise additional capital in 2025.

FDA Approval for Amendment to SOL-1 Protocol

Received FDA approval for an amendment in SOL-1 to incorporate redosing at weeks 52 and 76, potentially increasing label flexibility to every six to 12 months.

Completion of SOL-1 Randomization

SOL-1 trial completed randomization ahead of schedule in December 2024 with 344 subjects.

Strong Patient Retention in SOL-1

Reported exceptional patient retention in SOL-1, with most rescue treatments aligning with prespecified criteria.

Financial Position and Cash Runway

Cash balance of $392 million as of December 31, 2024, with a cash runway into 2028.

Expansion Opportunities in NPDR and DME

Positive results from the HELIOS trial in NPDR and DME, with FDA feedback on clinical trial design expected in the first half of 2025.

Ocular Therapeutix (OCUL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OCUL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2025	2025 (Q2)	-0.35 / -	-0.26	―	―	―
May 05, 2025	2025 (Q1)	-0.29 / -0.38	-0.49	22.45% (+0.11)	―	―
Mar 03, 2025	2024 (Q4)	-0.25 / -0.29	-0.35	17.14% (+0.06)	―
Nov 14, 2024	2024 (Q3)	-0.24 / -0.22	-0.006	-3566.67% (-0.21)	―
Aug 07, 2024	2024 (Q2)	-0.22 / -0.26	-0.26	0.00% (0.00)	―
May 07, 2024	2024 (Q1)	-0.19 / -0.49	-0.39	-25.64% (-0.10)	―	―
Mar 11, 2024	2023 (Q4)	-0.30 / -0.35	-0.2	-75.00% (-0.15)	―	―
Nov 07, 2023	2023 (Q3)	-0.29 / >-0.01	-0.31	98.06% (+0.30)	―
Aug 07, 2023	2023 (Q2)	-0.30 / -0.26	-0.25	-4.00% (-0.01)	―
May 08, 2023	2023 (Q1)	-0.26 / -0.39	-0.16	-143.75% (-0.23)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

OCUL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 05, 2025	$8.80	$7.73	-12.16%
Mar 03, 2025	$7.14	$5.92	-17.09%
Nov 14, 2024	$10.60	$9.92	-6.42%
Aug 07, 2024	$7.89	$8.37	+6.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ocular Therapeutix (OCUL) report earnings?

Ocular Therapeutix (OCUL) is schdueled to report earning on Aug 05, 2025, After Close (Confirmed).

What is Ocular Therapeutix (OCUL) earnings time?

Ocular Therapeutix (OCUL) earnings time is at Aug 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is OCUL EPS forecast?

OCUL EPS forecast for the fiscal quarter 2025 (Q2) is -0.35.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing